Company Filing History:
Years Active: 2025
Title: Christopher Ungerer: Innovator in Therapeutic Proteins
Introduction
Christopher Ungerer is a notable inventor based in Langen, Germany. He has made significant contributions to the field of therapeutic proteins, particularly in the development of recombinant coagulation factors. His work is essential for advancing treatments for patients with Hemophilia A.
Latest Patents
Christopher Ungerer holds a patent for a de-immunized factor VIII molecule and pharmaceutical compositions comprising the same. This invention relates to recombinant Factor VIII (FVIII) proteins that have specific point mutations to reduce immunogenicity while retaining coagulant activity. The patent also includes nucleic acids encoding the de-immunized protein, cell lines, and methods for recombinant preparation. These innovations are particularly beneficial for treating patients with Hemophilia A, including those who have not previously received FVIII products and those who have developed an immune response to FVIII.
Career Highlights
Christopher Ungerer is associated with Biotest AG, where he continues to work on innovative solutions in the field of therapeutic proteins. His research focuses on creating safer alternatives for patients undergoing immune-tolerance-induction therapy and rescue ITI.
Collaborations
He collaborates with colleagues such as Karina Winterling and Steffen Kistner, contributing to a dynamic research environment that fosters innovation in therapeutic solutions.
Conclusion
Christopher Ungerer is a key figure in the development of therapeutic proteins, with a focus on improving treatment options for patients with Hemophilia A. His contributions through patents and collaborations highlight the importance of innovation in healthcare.